Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments

Alexandria Real Estate Equities underscores its support for blood cancer innovation through tenant R&D, early-stage investing and long-term nonprofit partnerships.

Rhea-AI Summary

Alexandria Real Estate Equities (ARE) is marking Blood Cancer Awareness Month by spotlighting its role in enabling blood cancer R&D, philanthropy and strategic investments.

The company highlights tenant Juno Therapeutics, an early CAR-T innovator that helped advance Breyanzi®, an FDA-approved therapy for certain relapsed or refractory B-cell blood cancers, and notes its early venture investment ahead of Juno’s 2014 IPO at an approximate $2.2 billion market capitalization. Alexandria also details more than a decade of engagement with leading oncology and hematology nonprofits, including the Multiple Myeloma Research Foundation, Blood Cancer United, the National Marrow Donor Program and several major cancer centers, as well as employee volunteer programs supporting blood, platelet and bone marrow donations and campus blood drives.

Market Context

ARE's -0.43% reaction to the July 29 partnership milestone offered a recent reference for a mission-...

Analysis

ARE's -0.43% reaction to the July 29 partnership milestone offered a recent reference for a mission-oriented announcement. The current release likewise provides no operating figures; future filings could clarify investment benefits, while recent net selling remains context.

Key Figures

Blood cancer types: over 100 types Diagnosis frequency: every three minutes Share of new cancers: 9.4% +5 more

8 metrics

Blood cancer types over 100 types Blood cancers

Diagnosis frequency every three minutes Leukemia, lymphoma or myeloma in the U.S.

Share of new cancers 9.4% All new cancers in the United States in 2025

Mortality frequency every nine minutes U.S. blood cancer deaths

People living with or in remission over one million people Blood cancers in the U.S.

Juno IPO year 2014 Juno went public

Juno IPO market capitalization approximately $2.2 billion At its 2014 initial public offering

Juno acquisition year 2018 Juno was acquired by Celgene

Historical Context

5 past events · Latest: Sep 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Cash dividend declaration	Positive	+0.6%	Quarterly cash dividend matched the prior quarter and preceded a positive 24-hour response.
Aug 25	Conference call scheduling	Neutral	-2.1%	Third-quarter results conference-call scheduling preceded a negative 24-hour price reaction.
Aug 12	Debt offering pricing	Neutral	+0.8%	Priced $1 billion of junior subordinated notes in a registered public offering.
Aug 03	Second-quarter earnings	Negative	-7.8%	Reported lower FFO, real-estate impairments and declining same-property NOI.
Jul 29	Partnership milestone	Positive	-0.4%	MAP-D completed its design phase within a planned depression research initiative.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed mixed responses across dividend, financing, earnings and partnership announcements.

Key Terms

hematologic cancers, car-t therapies, relapsed or refractory, cell therapy

4 terms

hematologic cancers medical

"Blood cancers, also known as hematologic cancers, begin in blood-forming tissue"

Hematologic cancers are cancers that start in the blood, bone marrow, or lymphatic system — the body’s blood- and immune-system factories — and include diseases such as leukemia, lymphoma and myeloma. They matter to investors because advances, clinical trial results, regulatory approvals or safety setbacks can rapidly change a company’s future revenue and valuation; think of a successful therapy as a new, high-demand product that can reshape sales and long-term profits.

car-t therapies medical

"An early leader in CAR-T therapies, Juno helped advance the science"

CAR-T therapies are cancer treatments that reprogram a patient’s own immune cells to recognize and attack tumors, like turning ordinary soldiers into guided missiles aimed at specific cancer markers. They matter to investors because they can offer dramatic, long-lasting benefits for hard-to-treat cancers but involve high research and manufacturing costs, complex logistics, regulatory scrutiny, and pricing debates that can drive significant commercial upside or downside.

relapsed or refractory medical

"FDA-approved CAR-T cell therapies for relapsed or refractory B-cell blood cancers"

"Relapsed or refractory" describes a situation where a disease, such as an illness or condition, returns after treatment or does not respond to initial treatment efforts. For investors, this indicates ongoing challenges or setbacks in managing the disease, which can affect the success of related treatments or therapies and impact the potential value of associated companies or products. Understanding this helps gauge the stability and future prospects of medical developments or healthcare investments.

cell therapy medical

"a global nonprofit leader in cell therapy that connects patients"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PASADENA, Calif., Sept. 4, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today recognizes Blood Cancer Awareness Month by highlighting its strategic investments and tenants developing life-saving therapies in hematology and oncology, as well as the company's longstanding mission-critical engagement with the nation's leading nonprofits focused on blood cancers. Blood cancers, also known as hematologic cancers, begin in blood-forming tissue, such as bone marrow, or in cells of the immune system. There are over 100 types of blood cancers, including leukemia, lymphoma and myeloma.

"According to Blood Cancer United, someone is diagnosed with leukemia, lymphoma or myeloma approximately every three minutes, representing 9.4% of all new cancers in the United States in 2025. And they remain a major cause of cancer mortality; someone in the U.S. dies from blood cancer approximately every nine minutes. There has been meaningful progress, and survival rates have improved substantially with over one million people in the U.S. living with or in remission from blood cancers, but continued investment and collaboration remain essential," said Peter Moglia, chief executive officer and chief investment officer of Alexandria Real Estate Equities, Inc. "Blood Cancer Awareness Month is more than a moment for recognition and reflection; it is a call to action to accelerate research, improve access and support patients and families. We are honored to partner with consequential nonprofit organizations focused on oncology and hematology, and deeply proud of Alexandria's mission-critical role in enabling our tenants and investments to develop life-changing treatments and cures."

Juno Therapeutics (Juno), Alexandria's longstanding tenant in Seattle, represents one of the defining success stories in blood cancer innovation. An early leader in CAR-T therapies, Juno helped advance the science behind Breyanzi®, one of the leading FDA-approved CAR-T cell therapies for relapsed or refractory B-cell blood cancers, with approvals across multiple lymphoma indications and marketed by Bristol Myers Squibb. Alexandria Venture Investments was also an early investor in Juno, which went public in 2014 at an IPO market capitalization of approximately $2.2 billion and was acquired by Celgene in 2018; Celgene was later acquired by Bristol Myers Squibb in 2019.

For over a decade, Alexandria has engaged with nonprofits advancing research, patient advocacy and access across oncology and hematology, including the Multiple Myeloma Research Foundation (MMRF), Blood Cancer United, the National Marrow Donor Program (NMDP), Alliance for Cancer Gene Therapy, Fred Hutch Cancer Center, Curebound, UCSD Health's Moores Cancer Center and Memorial Sloan Kettering Cancer Center. In 2012, Alexandria began its partnership with the MMRF, the largest nonprofit solely focused on accelerating a cure for multiple myeloma patients, with Joel Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc., serving on its board from 2014 to 2017. Alexandria is proud to support the MMRF at the nonprofit's Blood Cancer Awareness event at the Alexandria Center® for Life Science – New York City megacampus this month. Through Alexandria's corporate social responsibility initiatives, the company and its employees also support NMDP, formerly Be The Match, a global nonprofit leader in cell therapy that connects patients to life-saving donors and advances research to improve patient outcomes. Alexandria employees may use company-provided Volunteer Time Off to donate blood, platelets or bone marrow, and the company regularly coordinates blood drives across its collaborative campuses for both its employees and tenants.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's corporate responsibility initiatives, strategic investments, partnerships and support of charitable and community organizations; Alexandria's role in supporting tenants and companies in which it invests that are engaged in research and development in hematology and oncology; and the anticipated impact or benefits of these investments, partnerships and support, including the expected impact of the missions, programs and initiatives of the charitable and community organizations Alexandria supports. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Sara Cohen, Assistant Vice President – Capital Markets & Corporate Operations, (646) 799-2617, scohen@are.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-highlights-its-role-in-advancing-blood-cancer-innovation-by-enabling-life-changing-tenant-rd-mission-critical-philanthropic-initiatives-and-strategic-investments-302869252.html

SOURCE Alexandria Real Estate Equities, Inc.

FAQ

What did Alexandria Real Estate Equities (ARE) announce for Blood Cancer Awareness Month?

Alexandria Real Estate Equities announced that it is recognizing Blood Cancer Awareness Month by highlighting its tenants’ hematology and oncology R&D, its early strategic investments in blood cancer innovators and its longstanding partnerships with leading nonprofits focused on blood cancer research, patient advocacy and access.

How is Alexandria Real Estate Equities (ARE) involved in blood cancer therapy development?

Alexandria is the landlord of Juno Therapeutics, an early leader in CAR-T therapies that helped advance Breyanzi®, an FDA-approved CAR-T cell therapy for certain relapsed or refractory B-cell blood cancers. Alexandria Venture Investments was also an early investor in Juno prior to its 2014 IPO.

Which nonprofits does Alexandria Real Estate Equities (ARE) support in blood cancer and oncology?

Alexandria supports nonprofits including the Multiple Myeloma Research Foundation, Blood Cancer United, the National Marrow Donor Program, Alliance for Cancer Gene Therapy, Fred Hutch Cancer Center, Curebound, UCSD Health's Moores Cancer Center and Memorial Sloan Kettering Cancer Center through donations, events and other engagement.

What is Alexandria Real Estate Equities’ relationship with the Multiple Myeloma Research Foundation?

Alexandria has partnered with the Multiple Myeloma Research Foundation since 2012. Joel Marcus, the company’s executive chairman and founder, served on the MMRF board from 2014 to 2017, and Alexandria is supporting the MMRF’s Blood Cancer Awareness event at its New York City life science megacampus.

How does Alexandria Real Estate Equities (ARE) involve employees in blood cancer-related initiatives?

Through its corporate social responsibility initiatives, Alexandria offers employees Volunteer Time Off to donate blood, platelets or bone marrow and regularly coordinates blood drives across its campuses for employees and tenants, supporting the National Marrow Donor Program and broader patient needs.

What blood cancer statistics does Alexandria Real Estate Equities highlight in this announcement?

The company cites data that in 2025 someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma approximately every three minutes, and someone dies from blood cancer about every nine minutes, while over one million people in the U.S. are living with or in remission from blood cancers.